Sequent Scientific Ltd

Meeting Details

• Date: August 12, 2026
• Type/Mode: Earnings conference call; virtual
• Event/Organizer: Viyash Scientific Limited Q1 FY’27 Earnings Conference Call

Participants

• Managing Director & Group Chief Executive Officer
• Executive Director & Chief Executive Officer, Animal Health
• Chief Financial Officer

Purpose

• Discuss Q1 FY’27 results; share highlights of business and financials
• Investor Q&A

Additional Notes

• Conference is being recorded
• Transcript will be available on company website within a week
• Results release and Investor Presentation uploaded on website and stock exchanges

Meeting Details

• Date of call: August 12, 2026.
• Type: earnings call; format: audio recording.
• Coverage: unaudited consolidated and standalone results for quarter ended June 30, 2026.

Participants

• Key participant: Company Secretary & Compliance Officer.

Purpose

• Discuss unaudited consolidated and standalone results for quarter ended June 30, 2026.

Additional Notes

• Recording available on the company website.

Business Overview

• Integrated pharmaceutical platform across human and animal health with API and formulation R&D.
• Backward integration across 16 manufacturing facilities for key APIs.
• Global footprint: 150+ countries and 250+ global customers.
• Companion animal focus expanding via Italy acquisition to access large EU market.
• Strategic growth: disciplined execution, efficiency, and long-term investments.

Operational Highlights

• Bio For Life acquisition SPA executed 21 July 2026; closing expected September 2026.
• Italy market access; salesforce covers 85% of vet clinics.
• Companion animal portfolio size ~85–90 products; expansion to core markets.
• Launches: 6 APIs and 4 FDFs across regions.
• Regulatory progress: 3 APIs (USDMF/EDMF/CEP) and 2 US FDF approvals.
• R&D scale: 85+ API and 24+ human FDF pipeline; 81+ animal FDF.
• Regulatory inspections: 4 regulatory audits; 66 customer audits.
• Manufacturing footprint: 16 facilities; ongoing backward integration.

Financial Performance

• Q1 FY27 revenue from operations ₹9,464 Mn, up 19.5% YoY.
• Gross margin 54.1%; EBITDA ₹2,047 Mn with 21.6% margin.
• PAT ₹793 Mn in Q1 FY27; YoY growth 114.9%.
• EBT ₹1,124 Mn; Taxes ₹331 Mn; Finance cost ₹125 Mn.
• FY26 revenue ₹34,203 Mn; YoY growth 14%.
• FY26 PAT ₹2,246 Mn; FY25 ₹158 Mn.
• Revenue mix highlights growth driven by Formulations and Emerging Markets.

Capital Structure & Liquidity

• Finance cost declined to ₹125 Mn in Q1 FY27 from ₹204 Mn prior year.
• No new debt or equity raise disclosed in quarter.

Strategic Priorities & Outlook

• Long-term strategy: disciplined execution, operational efficiency, and strategic investments for sustainable growth.
• Companion animal focus to drive growth via Italy and broader Europe.
• Pipeline: 85+ APIs and 81+ animal FDFs; opportunities in CDMO and oncology.
• M&A and geography expansion to sustain growth.

Risks & Mitigation

• Italy acquisition closing remains subject to regulatory approvals.
• Integration risks of Bio For Life; execution and regulatory timelines.
• Regulatory and market risks acknowledged; emphasis on disciplined execution.

Governance

• Chairman: Dr. Kamal Sharma; MD & CEO: Dr. Haribabu Bodepudi.
• Board includes independent directors; Company Secretary Yoshita Vora.
• No material governance changes disclosed.

AGM Details

• Forty-first AGM held on Aug 11, 2026 at 4:00 PM IST via VC/OAVM.
• Cut-off date for voting: Aug 4, 2026.
• Total shareholders on record: 133,984.
• Remote e-voting window: Aug 7-10, 2026.

Resolutions & outcomes

• Resolution 1: Adoption of Audited Financial Statements for FY2025-26 - passed; 1,214 against.
• Resolution 2: Re-appointment of Dr. Haribabu Bodepudi - passed; 421,263 against.
• Resolution 3: Re-appointment of Rajaram Narayanan - passed; 1,678 against.
• Resolution 4: Ratification of revised remuneration to Cost Auditor for FY2025-26 - passed; 1,680 against.
• Resolution 5: Ratification of remuneration to Cost Auditor for FY2026-27 - passed; 1,631 against.
• Resolution 6: Adoption of new Articles of Association - passed; 5,107 against.

Directors

• Directors re-appointed: Dr. Haribabu Bodepudi and Rajaram Narayanan.

Auditors

• Cost Auditor remuneration approved for FY2025-26 and FY2026-27.

AGM Details

• AGM held on 11 August 2026 at 4:00 PM via VC/OAVM.
• Meeting concluded at 4:55 PM IST.

Key Resolutions

• Adoption of Audited Financial Statements for year ended March 31, 2026 (Ordinary).
• Re-appointment of Dr. Haribabu Bodepudi as Director, retiring by rotation (Ordinary).
• Re-appointment of Rajaram Narayanan as Director, retiring by rotation (Ordinary).
• Ratification of remuneration payable to Cost Auditor for FY 2025-2026 (Ordinary).
• Ratification of remuneration payable to Cost Auditor for FY 2026-2027 (Ordinary).
• Adoption of a new set of Articles of Association (Special).

Voting Status

• Voting results to be announced within statutory timelines and intimated to stock exchanges.

Q1 FY27 highlights

• Revenues ₹9,464 million, up 19.5% year-on-year.
• EBITDA ₹2,047 million, up 59.2%.
• EBITDA margin 21.6% (EBITDA* before ESOP costs).
• PAT ₹793 million, up 114.9%.
• Net debt / EBITDA at 0.1x.

Strategic developments

• Bio For Life acquisition in Italy expands companion animal platform.
• Acquisition provides market access and European product-launch platform.
• Integration supports growth strategy and improved operating leverage.
• Earnings call scheduled for Aug 12, 2026 at 3:30 PM IST.

Outlook & execution

• Management targets disciplined execution and operational efficiency for sustainable growth.

Financial results approved

• Unaudited standalone and consolidated results for quarter ended 30 June 2026 approved.
• Limited Review Report from Statutory Auditors attached.

ESOP and capital raise

• Allotted 10,30,775 equity shares under ESOP Scheme 2026 at Rs 101 per share.
• Post allotment paid-up capital raised to Rs 87,98,15,176; 43,99,07,588 shares.

Rights issue to AAHL

• Approved subscription to AAHL rights issue up to Rs 400,02,15,648.
• Intercompany loan adjustment to fund subscription; no change in AAHL ownership.

Vietnam subsidiary incorporation

• Approved incorporation of a step-down subsidiary in Vietnam via AAHL or AAHL Ireland.

BioForlife Italia acquisition plan

• SPA signed to acquire BioForlife Italia; EUR 16.976 million, subject to approvals.

Amalgamation restatement and ESOP details

• Comparatives restated due to Composite Scheme; auditor conclusions not modified.
• ESOP 2026 adoption enabled; 13,098,000 options granted (2.8% of post-amalgamation paid-up capital).
• Incremental expense of about Rs 191-193 million recognized for the quarter.

AGM and AR access

• 41st AGM scheduled for 11 August 2026 at 4:00 PM IST via VC/OAVM.
• Annual Report 2025-26 and AGM notice available at the company website.
• Letter sent to shareholders without registered email providing AR link.
• AR/Notice also accessible on BSE/NSE and NSDL websites.
• Non-registered email holders urged to register with KFin Technologies for e-communications.
• KYC updation per SEBI circular; demat holders to update with their DP.
• Encourages electronic communications and digital dividends.